Yahoo · Aug 13, 2026
LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.
RG
NASDAQ · RGEN
Repligen Corporation
Healthcare · Medical - Instruments & Supplies
$166.15
Down-$2.89 (-1.71%)
Updated Aug 19, 2026, 10:49 AM
SID Score
6.3/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 9.1B
- P/E ratio
- 5,229.48
- Dividend yield
- 0.00%
- 52-week range
- $100.99 – $175.77
- Volume
- 462.72K
- Avg. volume
- 934.31K
Price performance
RGEN price history
1M range · 21 trading sessions · Daily adjusted prices
RGEN closed at $166.15 after 21 trading sessions, up 21.29% for the selected period.
- Last close
- $166.15
- Period change
- +21.29%
- Period low
- $131.06
- Period high
- $169.04
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 18, 2026 | $168.01 | $168.03 | $164.83 | $166.15 | 462.72K |
| Aug 17, 2026 | $166.25 | $169.495 | $164.62 | $169.04 | 658.9K |
| Aug 14, 2026 | $167.49 | $168.015 | $165.05 | $166.83 | 598.13K |
| Aug 13, 2026 | $167.19 | $168.3725 | $161.895 | $167.49 | 762.3K |
| Aug 12, 2026 | $165.21 | $166.955 | $162.36 | $165.70 | 833.92K |
| Aug 11, 2026 | $163.41 | $168.20 | $161.02 | $164.77 | 989.27K |
| Aug 10, 2026 | $163.06 | $166.43 | $160.99 | $163.17 | 770.77K |
| Aug 7, 2026 | $159.44 | $164.97 | $159.44 | $163.90 | 950.5K |
| Aug 6, 2026 | $156.21 | $162.37 | $156.085 | $159.44 | 1.22M |
| Aug 5, 2026 | $150.00 | $158.95 | $149.94 | $158.59 | 1.28M |
| Aug 4, 2026 | $146.76 | $149.97 | $142.29 | $149.78 | 1.2M |
| Aug 3, 2026 | $142.06 | $147.38 | $140.54 | $147.06 | 1.01M |
| Jul 31, 2026 | $143.81 | $145.00 | $139.3975 | $141.01 | 875.27K |
| Jul 30, 2026 | $143.67 | $144.18 | $139.98 | $143.60 | 1.04M |
| Jul 29, 2026 | $144.24 | $149.73 | $140.265 | $141.23 | 1.51M |
| Jul 28, 2026 | $139.70 | $154.00 | $137.35 | $145.34 | 2.51M |
| Jul 27, 2026 | $131.87 | $133.355 | $130.03 | $131.06 | 1.46M |
| Jul 24, 2026 | $138.13 | $138.13 | $131.82 | $131.96 | 1.36M |
| Jul 23, 2026 | $144.23 | $148.37 | $132.28 | $137.60 | 2.79M |
| Jul 22, 2026 | $131.76 | $142.48 | $131.1725 | $140.09 | 2.69M |
| Jul 21, 2026 | $131.95 | $138.07 | $129.00 | $136.99 | 2.14M |
Latest RGEN news
The latest Smart Investors Daily articles mentioning RGEN.
Stock researchCompany · Overview
RGEN research
Overview
Company profile and research snapshot.
Company profile
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $171.00
- Implied upside
- —
- Analysts
- 28
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | Wells Fargo | Overweight | — |
| Jul 29, 2026 | JP Morgan | Overweight | — |
| Jul 7, 2026 | Benchmark | Buy | — |
| Jul 6, 2026 | Evercore ISI Group | Outperform | — |
| Jun 3, 2026 | HSBC | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 13, 2026
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.
Yahoo · Aug 12, 2026
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know
Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.
Yahoo · Aug 12, 2026
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
